Live Breaking News & Updates on Jennifer Lachey

Stay updated with breaking news from Jennifer lachey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Jennifer Lachey Sells 7,950 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) Stock

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) insider Jennifer Lachey sold 7,950 shares of the firm’s stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $60.00, for a total value of $477,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through […] ....

United States , Jennifer Lachey , Thomson Reuter , Nisa Investment Advisors , Keros Therapeutics Inc , Zacks Investment Research , Deutsche Bank , America Corp , Royal Bank , Keros Therapeutics , Get Rating , Investment Research , State Teachers Retirement System , Investment Advisors , Nasdaq Kros , Insider Trading , Nsider Trades ,

Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $63.27

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) gapped up prior to trading on Thursday . The stock had previously closed at $63.27, but opened at $66.75. Keros Therapeutics shares last traded at $66.95, with a volume of 22 shares changing hands. Several research firms recently issued reports on KROS. HC Wainwright restated a […] ....

Jennifer Lachey , Keros Therapeutics Inc , Securities Exchange Commission , Keros Therapeutics Company Profile , Zacks Investment Research , Citadel Advisors , Meitav Dash Investments Ltd , Keros Therapeutics , Get Rating , Investment Research , Exchange Commission , Track Capital , Dash Investments , Therapeutics Company Profile , Nasdaq Kros ,

Jefferies Financial Group Weighs in on Keros Therapeutics, Inc.'s Q2 2022 Earnings (NASDAQ:KROS)

Keros Therapeutics, Inc. (NASDAQ:KROS – Get Rating) – Research analysts at Jefferies Financial Group issued their Q2 2022 earnings per share (EPS) estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Thursday, March 10th. Jefferies Financial Group analyst E. Yang anticipates that the company will post earnings per […] ....

United States , Jennifer Lachey , Julius Knowles , Keros Therapeutics Inc , Securities Exchange Commission , Zacks Investment Research , Ensign Peak Advisors Inc , Nisa Investment Advisors , Jefferies Financial Group , Macquarie Group Ltd , Royal Bank , Keros Therapeutics , Get Rating , Financial Group , Investment Research , Investment Advisors , Peak Advisors Inc , Arizona State Retirement System , Director Julius Knowles , Exchange Commission , Nasdaq Kros , Earnings Estimates , Jefferies Financial Group Inc ,

Keros Therapeutics (NASDAQ:KROS) Earns "Buy" Rating from HC Wainwright

Keros Therapeutics (NASDAQ:KROS – Get Rating)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Thursday, TipRanks reports. They currently have a $100.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 89.00% from the company’s previous close. […] ....

United States , Jennifer Lachey , Julius Knowles , Nisa Investment Advisors , Keros Therapeutics Inc , Securities Exchange Commission , Zacks Investment Research , Deutsche Bank , America Corp , Royal Bank , Keros Therapeutics , Get Rating , Director Julius Knowles , Exchange Commission , State Teachers Retirement System , Investment Advisors , Nasdaq Kros , Reiterated Rating , Hc Wainwright ,